A Multicenter, Open-Label, Randomized, Phase II Trial of Adjuvant Dasatinib Plus Gemcitabine Versus Single-Agent Gemcitabine in Patients With Resected Pancreatic Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Dasatinib (Primary) ; Gemcitabine (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 12 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2017.
- 12 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.